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Background: The BRAF V600E mutation is reportedly associated with inferior survival among colon cancer
patients. Here we report a patient with rectal cancer who carried the novel BRAF mutation VK600–601E, which has
analogous molecular functions to those of the conventional BRAF mutation V600E, and may have potential as a
prognostic marker for colorectal cancer (CRC).
Case presentation: The present 65-year-old male patient was diagnosed with recurrent rectal adenocarcinoma
(stage II by AJCC TNM staging 7th edition) 14 months after surgery and was treated with modified FOLFOX6
(fluorouracil, leucovorin, and oxaliplatin), radiation, and FOLFIRI (fluorouracil, leucovorin, and irinotecan). The
tumor progressed before further treatment could be initiated, resulting in death after 15 months. This survival
period was similar to the median overall survival among patients with metastatic CRC and BRAF mutations
who were treated with the FOLFIRI regimen with or without cetuximab.
Conclusions: Thus, the BRAF VK600–601E mutation may lead to an aggressive clinical course in CRC patients
suffering from rapid progression and potential resistance to multiple therapeutic modalities.
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Prognoses for patients with colorectal cancer (CRC) have
improved significantly with the introduction of molecular-
targeted drugs such as anti-epidermal growth factor
receptor agents (anti-EGFR). First-line treatment with the
anti-EGFR cetuximab in addition to FOLFIRI (fluoroura-
cil, leucovorin, and irinotecan) reduced the risk of pro-
gression of metastatic colorectal cancer compared with
FOLFIRI treatment alone. However, the benefit of cetuxi-
mab was limited to patients with KRAS (codon 12 and 13)
wild-type tumors [1]. S Tejpar et al. recently reported a
number of candidate markers that influence the response
to anti-EGFR, even among patients with wild type KRAS,
including new KRAS mutations (codon 61 and 146) and
mutations in BRAF and NRAS [2]. Although the best* Correspondence: takeshin@cc.okayama-u.ac.jp
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important, other KRAS mutations, such as those on
codons 61 and 146, have received recent attention.
BRAF is a member of the RAF family of kinases and
operates by binding to RAS [3]. A recent retrospective
study of several clinical trials demonstrated that the pres-
ence of the BRAF V600E mutation was a strong prognos-
tic factor for overall survival (OS) in patients with stage
II/III CRC, particularly for tumors with low or stable
microsatellite instability (MSI-Low, MSI-Stable, or no
MSI) [4]. Activating mutations in the BRAF gene are
almost within the kinase domain and produce a signaling
substitution of valine for glutamic acid at position 600
(V600E) [5]. However, in the present rectal cancer patient
with wild-type KRAS and no MSI, we discovered a novel
BRAF mutation that led to a triplet deletion of the coding
nucleotides 1799–1801 (TGA1799–1801 deletion; VK600–
601E). This patient demonstrated relatively poor responses
to conventional chemotherapy. Although this mutationis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and other novel RAS mutations (KRAS codons 61 and 146
or NRAS) may provide essential prognostic markers that
can be used to individualize treatment regimens for CRC
patients.
Case presentation
A 65-year-old man presented with perineal pain, polla-
kiuria, and a serum carbohydrate antigen 19–9 level of
564.3 IU/mL (normal, <39.9 IU/mL). He had undergone
a resection without preoperative chemoradiotherapy for
a 4 × 4.5-cm rectal adenocarcinoma lesion 14 months
previously, which was graded as IIA (T3N0M0) accord-
ing to the AJCC TNM classification [6]. According to
the surgical report, abdominoperineal resection with lat-
eral lymph nodes resection and inferior mesenteric artery
lymph node resection had done. Computed tomography
(CT) and positron emission tomography (PET)/CT
revealed a 3.5 × 3.0 × 2.7-cm perineal metastatic lesion
obstructing the right ureter. Metastases were observed inSep,2007 Nov,2008 Dec,2008 Feb,2009
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Figure 1 Timeline of a rectal cancer patient with the BRAF VK600–601
histopathological examination of the resected tumor following initial su
adenocarcinoma. PET/CT slices show recurrent tumors; progressive peri
right internal iliac lymph node metastases (the red arrows). The tumors
duct. The perineal metastatic tumor was enlarged and had invaded thethe right obturator lymph node, and the largest lesion
measured 4.0 × 3.3 × 3.0 cm. The metastatic lymph node
had infiltrated the right internal iliac artery (Figure 1).
After stent placement in the ureter, four cycles of a
modified FOLFOX6 regimen (mFOLFOX6) comprising
85 mg/m2 oxaliplatin, 200 mg/m2 leucovorin, 400 mg/m2
5-fluorouracil (5FU) bolus on day 1 and 2400 mg/m2 5FU
as a 46-h continuous infusion were administered at 2-
week intervals. Subsequently, the patient experienced
lower back pain, and a second PET/CT examination indi-
cated tumor recurrence and lymph node metastases on
one side of the pelvis. Chemotherapy was terminated and
radiotherapy (30 fractions at 2 Gy per day; total, 60 Gy)
was initiated. Upon pain relief, mFOLFOX6 therapy was
reinitiated according to the previous regimen, and no
signs of disease progression were observed until 10 months
later. At this point PET/CT scans revealed that the
perineal metastatic tumor had enlarged to approximately
9 cm (Figure 1), and the patient was hospitalized and




E mutation. The left lower image shows the findings of the
rgery in 2007, revealing a moderately to poorly differentiated
neal metastatic tumor (the white arrow) and right obturator and
had infiltrated into the right internal iliac artery and right urinary
bladder (yellow arrow).
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on day 1 and 2400 mg/m2 5FU as a 46-h continuous infu-
sion. One week later, the patient developed grade 4 neu-
tropenia (<500/mm3; Common Terminology Criteria for
Adverse Events ver. 4.0).
Between treatments, DNA was extracted from sections
of the primary tumor tissue and analyzed for KRAS and
BRAF mutations and MSI [7]. No MSI or mutations at
codons 12 or 13 of KRAS were identified. Direct sequen-
cing for BRAF revealed a triplet nucleotide deletion
(TGA) in coding nucleotides 1799–1801 (Figure 2). This
mutation resulted in the deletion of amino acid 601 (ly-
sine) and a valine–glutamate substitution at position 600
(VK600–601E).
After recovery from severe neutropenia, the perineal
metastatic tumor had grown rapidly and had invaded
the bladder (Figure 1), and consequent severe hematuria
and nephropyelitis resulted in renal failure. Despite ther-
apy for renal failure, the patient died 15 months after
initiation of first-line therapy for tumor recurrence.
Conclusions
CRC development is considered a multistep process that
follows the accumulation of genetic alterations, including
chromosomal abnormalities, gene mutations, and epi-
genetic changes [4]. The Ras–Raf–MAP kinase pathway is
known to mediate cellular responses to extracellularFigure 2 BRAF mutation analysis of the primary tumor. (a) Direct sequ
triplet deletion from T1799 to A1801. (b) Schematic representation of the BRA
conserved regions. The kinase activation segment is located between codonssignals that regulate cell proliferation, differentiation, and
apoptosis [8]. KRAS-activating mutations decrease or
abolish the intrinsic GTPase activity of the KRAS protein,
leading to its constitutive activation. Similarly, the BRAF
V600E mutation induces structural changes that increase
the kinase activity of the RAF protein [9]. Moreover, tu-
mors with RAS oncogene mutations are resistant to treat-
ments with EGFR inhibitors, indicating that mutations in
the RAS proto-oncogene are predictive of treatment re-
sponses [4,10]. RAS mutations commonly occur in codons
12 and 13 and are implicated in many human cancers,
including approximately 40% of CRC cases [3]. In 2002,
Davies et al. [5] identified activating mutations in BRAF
that were present in many human cancers, including ap-
proximately 10% of CRC cases. The BRAF V600E muta-
tion accounts for 80% of BRAF mutations in human
cancers and is thought to be biologically distinct from less
frequent BRAF mutations because it allows growth in the
absence of functional RAS genes [5]. Interestingly, the
BRAF V600E mutation has not been previously reported
in combination with the KRAS mutation in patients with
CRC [3,11], suggesting that at least one of these pathways
must remain intact for cell survival.
The BRAF V600E mutation is known to be a strong
prognostic marker in patients with metastatic and stage
II/III CRC [4]. Similar to most activating mutations,
the BRAF VK600–601E mutation affects the activationencing chromatographs of the BRAF VK600–601E mutation demonstrating
F protein structure and various mutations. CR-1, −2, and −3 represent
594 and 623. Modified from Wan PT et al. [12].
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rupt the interaction between the activation segment and
P-loops that normally stabilize BRAF in the inactive
conformation [12,13]. Because the BRAF VK600–601E
mutation is functionally analogous to the BRAF V600E
mutation [14], it may be an additional marker of recur-
rence and poor treatment responses in patients with CRC.
In support of this hypothesis, the present CRC patient
responded poorly to conventional radiotherapy and
chemotherapy and died at 15 months after initiation of
first-line treatment for recurrence. This time period was
almost equal to the median overall survival of patients
with metastatic CRC with BRAF mutations who were
treated with the FOLFIRI regimen with or without cetuxi-
mab (14.0 and 10.3 months, respectively) [15]. Although
outcomes of rectal cancer often differ from those of colon
cancer, clinical trials for unresectable advanced colorectal
cancer always include colon and rectal cancer cases. For
example, in a randomized phase III study (CRYSTAL trial)
comparing FOLFIRI alone with cetuximab plus FOLFIRI
regimens in 348 patients with KRAS exon2 wild-type
CRCs, rectal cancer cases comprised 40.9% and 44.2% of
the treatment arms, respectively [1].
To our knowledge, this is the first report describing
the BRAF VK600–601E mutation in a patient with CRC.
Although this mutation may be uncommon, the present
observations warrant routine investigation of alterna-
tive mutations among CRC patients who show rapid
progression and/or resistance to aggressive radiother-
apy and/or chemotherapy.
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